微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 19.36% | -10.57% | 4.92% | 133/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 18.46% | -7.51% | -8.9% | 142/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 20.26% | -5.1% | -3.38% | 140/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 20.97% | -3.25% | -3.16% | 141/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 21.65% | 2.81% | 8.51% | 136/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 19.96% | 0.92% | -6.53% | 141/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 21.35% | 0.82% | -1.5% | 138/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 21.68% | 0.97% | 2.91% | 137/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 21.06% | -6.41% | 6.52% | 132/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 19.77% | -11.85% | -6.63% | 143/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 21.18% | -8.08% | -1.35% | 135/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 21.47% | -7.64% | -4.61% | 140/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 22.5% | 1.41% | 0.32% | 131/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 22.43% | 0.05% | -2.64% | 142/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 23.04% | 3.95% | -0.88% | 127/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 23.24% | 17.14% | 4.74% | 133/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 22.19% | 33.16% | -1.03% | 120/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 22.42% | -4.98% | 1.17% | 137/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 22.16% | -14.53% | 11.69% | 111/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 19.84% | -21.41% | 19.07% | 126/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 16.66% | -26.56% | -29.38% | 108/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 23.6% | -1.75% | -8.99% | 128/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 25.93% | 4.18% | 2.69% | 100/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 25.25% | -0.96% | 11.27% | 107/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 22.69% | -10.26% | -5.52% | 99/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 24.02% | 8.35% | -3.5% | 125/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 24.89% | 17.91% | -2.37% | 98/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 25.49% | 19.9% | 0.81% | 102/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 25.29% | 28.05% | 14.08% | 97/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 22.17% | 8.12% | 5.02% | 116/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 21.11% | -0.45% | -0.72% | 93/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 21.26% | -2.38% | 7.66% | 98/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 19.75% | -5.69% | -3.68% | 85/159 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 20.5% | -6.66% | -3.3% | 107/159 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 21.2% | -10.29% | -2.65% | 76/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 21.78% | -11.46% | 4.02% | 84/159 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 20.94% | -9.49% | -4.67% | 71/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 21.97% | -9.34% | -7.06% | 95/159 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 23.63% | -7.42% | -3.93% | 67/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 24.6% | -5.97% | 6.33% | 70/159 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 23.14% | 6.62% | -4.5% | 63/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |